Get in Touch

This site is intended for UK healthcare professionals only and contains promotional information.UK Flag Please visit the MHRA Yellowcard site to report an Adverse Event.

Home/Therapy areas/Diabetes and Endocrinology/Diabetes and Endocrinology Webinars and HCP Resources/The role of SGLT2is in the GLP1-RA shortage

The role of SGLT2is in the GLP1-RA shortage

Invokana®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

  • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC. 

Prescribing Information can be found under Useful Resources

The role of SGLT2is in the GLP1-RA shortage - Vicki Alabraba

Diabetes Specialist Nurse, Vicki Alabraba, talks about how she has used SGLT2is for the management of her type 2 diabetic patients during the GLP1-RA shortage. She focuses on the effectiveness of canagliflozin for HbA1c reduction alongside other beneficial characteristics.

This presentation was part of The Many Faces of Diabetes national webinar on the 14th of November 2023, titled “Primary Prevention in Primary Care.

Useful Resources

Vicki Alabraba- MSc Diabetes Practice, BSc (Hons) Nursing, RN Independent Prescriber

Vicki Alabraba- MSc Diabetes Practice, BSc (Hons) Nursing, RN Independent Prescriber

Vicki been a diabetes specialist nurse for 18 years with experience across both primary and secondary care across the UK. She currently works within the Eden team at Leicester Diabetes Centre writing and delivering diabetes education to primary care HCP’s both locally and nationally. Vicki also works clinically as DSN in primary care. Vicki is a member of DSN Forum UK leadership team and a committee member for the Primary Care Diabetes Society. Vicki is also a member of the voluntary MDT Diabetes 101 team which was set up during the COVID-19 pandemic to support people living with diabetes. She has a keen interest in type 2 diabetes in primary care, diabetes technology, type 3c diabetes and diabetes service development. Vicki was awarded the QiC Diabetes HCP of the year in 2020 and won two QiC Diabetes awards in 2021 with the Diabetes 101 team.

PP-IN-UK-1136 January 2024

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL.

Phone 0800 085 8678

Useful Links Edit Cookies Settings
Contact Us Get in Touch

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc.

 

This website is brought to you by A. Menarini Farmaceutica Internazionale SRL, a company registered in England and Wales under No. BR016024 with its registered office at Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, HP10 0HH.

Copyright © 2021 Menarini. All rights reserved. VAT number 143099806. PP-MN-UK-0549 May 2024